Astria’s Navenibart Granted FDA Orphan Designation for Hereditary Angioedema Treatment
In a breakthrough for rare disease treatment, Astria Therapeutics has secured an orphan-drug designation from the FDA for its...
Phase 1B/2 study
Kronos Bio’s Lanraplenib Study in Leukemia Patients Falls Short
Kronos Bio announced that data from its Phase 1B/2 study of lanraplenib in leukemia patients does not support continuing...
Kronos Bio Streamlines Operations to Extend Cash Runway
Kronos Bio, a clinical-stage biopharmaceutical company, is cutting 19% of its staff to extend its cash runway after positive...